Company Description
Phenomix hopes to create a pharmaceutical phenomenon by investigating and discovering new treatments for immune system ailments and metabolic...
Key Phenomix Financials
| Company Type | Private - NASDAQ (GM): PHMX Proposed Main Headquarters |
|---|---|
| 2006 Sales (mil.) | $0.0 |
| 2006 Employees | 43 |
More Phenomix Financials (4 pages)
Competition
Competitive Landscape for Biotechnology Sector
Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. The profitability of individual companies depends on the...
Read more about Phenomix's competition across multiple industries
Top Phenomix Competitors
Sponsored Links
The Business DirectoryTrading Toolbox
Phenomix Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| CEO and Director | Laura K. Shawver | Network | E-mail |
| EVP and COO | Christopher L. (Chris) Burnley | Network | E-mail |
| President | Julie M. Cherrington | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Current Phenomix News
- BioWorld Today July 3, 2008 [BioWorld Today] (03 Jul 2008 00:01:00 EDT)
- MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR [PCT Biblio Info] (17 Jun 2008 12:24:00 EDT)
- HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR [PCT Biblio Info] (17 Jun 2008 12:23:00 EDT)
Latest Industry Video
-
Rx For Cheap Drugs (4:04)
07/23/07 5:20PM ET - Miller Tabak & Co. Pharmaceuticals Analyst Les Fundleyder and Bain & Company Partner Tim Van Biesen discuss patent expirations affecting U.S. drug costs.







